The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Cord blood transplantation vs MMUD with PTCy in AML
Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses the finding of a study comparing cord blood transplantation versus mismatched unrelated donor (MMUD) with post-transplant cyclophosphamide (PTCy) in patients with acute myeloid leukemia (AML). The study found that there was a higher rate of non-relapse mortality (NRM) and graft failure in cord blood transplant recipients compared to MMUD recipients. In addition, the study found that the risk of graft-versus-host disease (GvHD) was lower in MMUD recipients treated with PTCy. Overall, this study strongly supports the use of MMUD transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
